(TWST) Twist Bioscience - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 3.998m USD | Total Return: 118.2% in 12m
Avg Turnover: 88.4M
Qual. Beats: -1
Rev. Trend: 99.7%
Qual. Beats: 3
Warnings
Altman Z'' -12.24 < 1.0 - financial distress zone
Extended 1w
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind
Twist Bioscience Corporation specializes in the high-throughput manufacturing of synthetic DNA using a proprietary silicon-based platform. The companys product portfolio includes synthetic genes, oligo pools, and immunoglobulin G proteins used across drug discovery, agriculture, and industrial chemical sectors. By miniaturizing the chemical process of DNA synthesis, the company reduces reagent consumption and increases production scale compared to traditional plastic-based methods.
The company also provides advanced tools for Next-Generation Sequencing (NGS), including library preparation kits and custom panels for cancer research and biomarker discovery. Beyond genomics, Twist is expanding into DNA-based data storage and antibody optimization services for biopharmaceutical clients. The synthetic biology sector often operates on a platform-as-a-service model, where centralized manufacturing lowers the barrier to entry for smaller biotech firms.
For a deeper look into the companys valuation metrics and growth outlook, ValueRay provides comprehensive analytical tools. Twist Bioscience maintains strategic collaborations to enhance its precision DNA libraries and remains a key supplier for viral research and diagnostic control materials.
- NGS portfolio expansion accelerates revenue growth in precision medicine and diagnostics
- Gross margin improvement depends on high-throughput DNA synthesis manufacturing efficiencies
- Biopharma services revenue growth relies on successful antibody discovery collaborations
- Synthetic biology demand fluctuates with venture capital funding in biotech sectors
- Long-term valuation hinges on commercial viability of DNA data storage technology
| Net Income: -81.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA -3.07 > 1.0 |
| NWC/Revenue: 49.69% < 20% (prev 75.78%; Δ -26.09% < -1%) |
| CFO/TA -0.08 > 3% & CFO -55.6m > Net Income -81.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.7m) vs 12m ago 3.44% < -2% |
| Gross Margin: 52.07% > 18% (prev 0.47%; Δ 5.16k% > 0.5%) |
| Asset Turnover: 64.39% > 50% (prev 58.37%; Δ 6.02% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.30 (Total Current Assets 323.4m - Total Current Liabilities 120.0m) / Total Assets 676.2m |
| B: -2.06 (Retained Earnings -1.39b / Total Assets 676.2m) |
| C: -0.13 (EBIT TTM -82.4m / Avg Total Assets 635.9m) |
| D: -6.31 (Book Value of Equity -1.39b / Total Liabilities 221.1m) |
| Altman-Z'' = -12.24 = D |
| DSRI: 1.09 (Receivables 64.2m/49.9m, Revenue 409.5m/347.7m) |
| GMI: 0.90 (GM 52.07% / 46.70%) |
| AQI: 1.42 (AQ_t 0.25 / AQ_t-1 0.18) |
| SGI: 1.18 (Revenue 409.5m / 347.7m) |
| TATA: -0.04 (NI -81.3m - CFO -55.6m) / TA 676.2m) |
| Beneish M = -2.71 (Cap -4..+1) = A |
As of May 28, 2026, the stock is trading at USD 64.17 with a total of 1,258,897 shares traded.
Over the past week, the price has changed by +29.64%,
over one month by +5.20%,
over three months by +36.76% and
over the past year by +118.19%.
Twist Bioscience has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy TWST.
- StrongBuy: 6
- Buy: 3
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 64.4 | 0.4% |
P/S = 9.2112
P/B = 8.2879
Revenue TTM = 409.5m USD
EBIT TTM = -82.4m USD
EBITDA TTM = -58.2m USD
Long Term Debt = 85.4m USD (estimated: total debt 95.8m - short term 10.4m)
Short Term Debt = 10.4m USD (from shortTermDebt, last quarter)
Debt = 95.8m USD (from shortLongTermDebtTotal, last quarter) (leases 95.8m already included)
Net Debt = -75.8m USD (calculated: Debt 95.8m - CCE 171.7m)
Enterprise Value = 3.92b USD (4.00b + Debt 95.8m - CCE 171.7m)
Interest Coverage Ratio = unknown (Ebit TTM -82.4m / Interest Expense TTM 0.0)
EV/FCF = -41.22x (Enterprise Value 3.92b / FCF TTM -95.1m)
FCF Yield = -2.43% (FCF TTM -95.1m / Enterprise Value 3.92b)
FCF Margin = -23.23% (FCF TTM -95.1m / Revenue TTM 409.5m)
Net Margin = -19.85% (Net Income TTM -81.3m / Revenue TTM 409.5m)
Gross Margin = 52.07% ((Revenue TTM 409.5m - Cost of Revenue TTM 196.3m) / Revenue TTM)
Gross Margin QoQ = 51.59% (prev 52.05%)
Tobins Q-Ratio = 5.80 (Enterprise Value 3.92b / Total Assets 676.2m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 95.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -65.1m (EBIT -82.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.70 (Total Current Assets 323.4m / Total Current Liabilities 120.0m)
Debt / Equity = 0.21 (Debt 95.8m / totalStockholderEquity, last quarter 455.1m)
Debt / EBITDA = 1.30 (negative EBITDA) (Net Debt -75.8m / EBITDA -58.2m)
Debt / FCF = 0.80 (negative FCF - burning cash) (Net Debt -75.8m / FCF TTM -95.1m)
Total Stockholder Equity = 465.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.78% (Net Income -81.3m / Total Assets 676.2m)
RoE = -4.37% (Net Income TTM -81.3m / Total Stockholder Equity 1.86b)
RoCE = -4.24% (EBIT -82.4m / Capital Employed (Equity 1.86b + L.T.Debt 85.4m))
RoIC = -12.32% (negative operating profit) (NOPAT -65.1m / Invested Capital 528.4m)
WACC = 12.57% (E(4.00b)/V(4.09b) * Re(12.87%) + D(95.8m)/V(4.09b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 3.19%
[DCF] Fair Price = unknown (Cash Flow -95.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.40 | # QB: -1
Revenue Correlation: 99.66 | Revenue CAGR: 22.84% | SUE: 2.05 | # QB: 3
EPS current Quarter (2026-06-30): EPS=-0.43 | Chg30d=-7.27% | Revisions=-56% | Analysts=8
EPS current Year (2026-09-30): EPS=-1.99 | Chg30d=-19.65% | Revisions=-64% | GrowthEPS=-53.1% | GrowthRev=+18.6%
EPS next Year (2027-09-30): EPS=-2.05 | Chg30d=-8.75% | Revisions=N/A | GrowthEPS=+4.3% | GrowthRev=+15.5%
[Analyst] Revisions Ratio: -64%